Hua Wu

Hua Wu

Auto-generated profile, based on publicly available information

Hua Wu

Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
HCHaojun Chen
Haojun Chen
YPYizhen Pang
Yizhen Pang
JWJingxun Wu
Jingxun Wu
LZLiang Zhao
Liang Zhao
BHBing Hao
Bing Hao
HWHua Wu
Hua Wu

1 February 2021 in Radiology
Verified
Journal Article
Closed access
YPYizhen Pang
Yizhen Pang
LZLiang Zhao
Liang Zhao
ZLZuoming Luo
Zuoming Luo
BHBing Hao
Bing Hao
HWHua Wu
Hua Wu
HCHaojun Chen
Haojun Chen
Gallium 68 fibroblast-activation protein inhibitor PET/CT had a higher tracer uptake and was superior to fluorine 18 fluorodeoxyglucose PET/CT in the detection of primary and metastatic lesions in ... Background Accurate clinical staging is crucial to managing gastrointestinal cancer, but fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT has limitations. Targeting fibroblast-activation protein i...

1 January 2016 in Theranostics
Verified
Journal Article
Open access
HCHaojun Chen
Haojun Chen
GNGang Niu
Gang Niu
HWHua Wu
Hua Wu
XCXiaoyuan Chen
Xiaoyuan Chen
Molecular imaging for non-invasive assessment of angiogenesisis is of great interest for clinicians because of the wide-spread application of anti-angiogenic cancer therapeutics. Besides, many other interventions that involve the change of blood vessel/tumor microenvironment would also benefit from such imaging strategies. Of the imaging techniques that target angiogenesis, radiolabeled Arg-Gly-Asp (RGD) peptides have been a major focus because of their high affinity and selectivity for integrin αvβ3--one of the most extensively examined target of angiogenesis. Since the level of integrin αvβ3 expression has been established as a surrogate marker of angiogenic activity, imaging αvβ3 expression can potentially be used as an early indicator of effectiveness of antiangiogenic therapy at the molecular level. In this review, we summarize RGD-based PET tracers that have already been used in clinical trials and intercompared them in terms of radiosynthesis, dosimetry, pharmacokinetics and clinical applications. A perspective of their future use in the clinic is also provided.

25 June 2020 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
HCHaojun Chen
Haojun Chen
LZLiang Zhao
Liang Zhao
DRDan Ruan
Dan Ruan
YPYizhen Pang
Yizhen Pang
BHBing Hao
Bing Hao
HWHua Wu
Hua Wu

6 October 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HFHao Fu
Hao Fu
JHJingxiong Huang
Jingxiong Huang
TZTianzhi Zhao
Tianzhi Zhao
HWHongjian Wang
Hongjian Wang
YCYuhang Chen
Yuhang Chen
HCHaojun Chen
Haojun Chen
Purpose: Fibroblast activation protein (FAP) is a promising target for tumor treatment. In this study, we aimed to investigate the safety and efficacy of the albumin binder-conjugated FAP-targeted radiopharmaceutical, 177Lu-EB-FAPI (177Lu-LNC1004), in patients with metastatic radioiodine-refractory thyroid cancer (mRAIR-TC). Patients and Methods: This open-label, non-randomized, first-in-human, dose-escalation, investigator-initiated trial had a 3+3 design and involved a 6-week 177Lu-LNC1004 treatment cycle in patients with mRAIR-TC at 2.22 GBq initially, with subsequent cohorts receiving an incremental 50% dose increase until dose-limiting toxicity (DLT) was observed. Results: 177Lu-LNC1004 administration was well tolerated, with no life-threatening adverse events observed. No patients experienced DLT in Group A (2.22 GBq/cycle). One patient experienced grade 4 thrombocytopenia in Group B (3.33 GBq/cycle); hence, another three patients were enrolled, none of whom experienced DLT. Two patients experienced grade 3 and 4 hematotoxicity in Group C (4.99 GBq/cycle). The mean whole-body effective dose was 0.17 ± 0.04 mSv/MBq. Intense 177Lu-LNC1004 uptake and prolonged tumor retention resulted in high mean absorbed tumor doses (8.50 ± 12.36 Gy/GBq). The mean effective half-lives for the whole-body and tumor lesions were 90.20 ± 7.68 and 92.46 ± 9.66 hours, respectively. According to RECIST, partial response, stable disease, and progressive disease were observed in 3 (25%), 7 (58%), and 2 (17%) patients, respectively. The objective response and disease control rates were 25% and 83%, respectively. Conclusions: FAP-targeted radioligand therapy with 177Lu-LNC1004 at 3.33 GBq/cycle was well tolerated in patients with advanced mRAIR-TC, with high radiation dose delivery to the tumor lesions, encouraging therapeutic efficacy, and acceptable side effects.

1 January 2016 in Theranostics
Verified
Journal Article
Open access
HCHaojun Chen
Haojun Chen
GWGuohao Wang
Guohao Wang
LLLixin Lang
Lixin Lang
OJOrit Jacobson
Orit Jacobson
DKDale O. Kiesewetter
Dale O. Kiesewetter
XCXiaoyuan Chen
Xiaoyuan Chen
The efficacy of therapeutic drugs is highly dependent on their optimal in vivo pharmacokinetics. Albumin conjugation is considered to be one of the most effective means of protracting the short lifespan of peptides and proteins. In this study, we proposed a novel platform for developing long lasting therapeutics by conjugating a small molecular albumin binding moiety, truncated Evans blue, to either peptides or proteins. Using the anti-diabetic peptide drug Exendin-4 as a model peptide, we synthesized a new long-acting Exendin-4 derivative (denoted as Abextide). Through complexation with albumin in situ, the biological half-life of Abextide was significantly extended. The hypoglycemic effect of Abextide was also improved remarkably over Exendin-4. Thus, Abextide has considerable potential to treat type 2 diabetes. This strategy as a general technology platform can be applied to other small molecules and biologics for the development of long-acting therapeutic drugs.